Over 31,000 women in London to be offered the at-home tests
News
Amgen looks to expand access to Otezla in the US
Company has submitted a supplemental new drug application for mild-to-moderate plaque psoriasis
UK sees a 20% growth in the number of advanced therapy trials, report finds
Cell and Gene Therapy Catapult report also found a surge in the number of commercially sponsored trials
MHRA approves Seagen’s Tukysa for HER2-positive breast cancer
Drug approved in a combination regimen for advanced breast cancer patients
Sanofi and GSK begin new study of their COVID-19 vaccine
Companies previously delayed vaccine programme in December 2020
Medica establishes joint venture partnership with Integral Diagnostics
Joint venture, MedX, will provide teleradiology reporting services
ONK Therapeutics enters collaboration with blood cancer charity Anthony Nolan
Agreement will aim to accelerate development of next-generation NK cell therapies
NHS to open mental health support hubs dedicated to staff
Services will be offered to staff who have been affected by the COVID-19 pandemic
AZ withdraws Imfinzi indication in the US for advanced bladder cancer
Decision made in consultation with the FDA following disappointing trial results
Avacta gets MHRA green-light to start phase I trial for ‘pro-drug’ chemotherapy
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta’s pre|CISION chemistry
New social media campaign launched to support COVID-19 vaccine roll-out in the UK
A range of Facebook frames and Instagram GIFs will be ready for use on social media today
Oxford University to develop Alzheimer’s disease treatments with Exscientia
Exscientia will use its AI-driven technology to generate novel clinical assets targeting neuroinflammation
GSK, Vir look beyond COVID-19 to develop new therapies for flu and other respiratory viruses
New agreement builds on existing collaboration to develop therapies for coronaviruses
COVID-19 collaborations could ‘unlock’ the potential of the UK’s life sciences sector
New report recommends continuing collaborations across the life sciences sector
EU approves Tukysa combo for advanced HER2-positive breast cancer
In the HER2CLIMB trial, Tukysa-treated patients had a 46% reduction in the risk of cancer progression or death
